Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs
23-Apr-2009
- United Kingdom
Vantia Therapeutics announced the appointment of Rachel Morten as Head of regulatory affairs.
Rachel has more than 24 years experience in global regulatory affairs and product development in the pharmaceutical and animal health industries. Most recently an independent regulatory affairs consultant, Rachel has also served as Senior Director, Group Head Regulatory Affairs for the international CRO Averion International Ltd (previously Hesperion). Previously Rachel founded ChapelPharma, a regulatory consultancy that was acquired by Hesperion in 2004.
Other news from the department people
